A1L11

Pimavanserin

Created:2024-05-24
Last modified:  2024-08-28

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count65
Chiral Atom Count0
Bond Count67
Aromatic Bond Count12
2D diagram of A1L11
Toggle HydrogenToggle Labels

Chemical Component Summary

NamePimavanserin
Synonyms1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
Systematic Name (OpenEye OEToolkits)1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
FormulaC25 H34 F N3 O2
Molecular Weight427.555
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESCACTVS3.385CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C3CCN(C)CC3)cc1
SMILESOpenEye OEToolkits2.0.7CC(C)COc1ccc(cc1)CNC(=O)N(Cc2ccc(cc2)F)C3CCN(CC3)C
Canonical SMILESCACTVS3.385 CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C3CCN(C)CC3)cc1
Canonical SMILESOpenEye OEToolkits2.0.7 CC(C)COc1ccc(cc1)CNC(=O)N(Cc2ccc(cc2)F)C3CCN(CC3)C
InChIInChI1.06 InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)
InChIKeyInChI1.06 RKEWSXXUOLRFBX-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB05316 
NamePimavanserin
Groups
  • approved
  • investigational
DescriptionPimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders.[L48236] Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors.[L48236] Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.[A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals.[A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized, placebo-controlled, parallel-group study.[L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous breakthrough designation.[L32913]
Synonyms
  • Pimavanserin
  • Pimavanserin tartrate
Brand Names
  • Nuplazid
  • Pimavanserin
IndicationPimavanserin is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.[L32883]
Categories
  • Amides
  • Antidepressive Agents
  • Central Nervous System Agents
  • Central Nervous System Depressants
  • Cytochrome P-450 CYP2D6 Substrates
ATC-CodeN05AX17
CAS number706779-91-1

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
5-hydroxytryptamine receptor 2AMDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSE...unknowninverse agonist
5-hydroxytryptamine receptor 2CMVNLRNAVHSFLVHLIGLLVWQSDISVSPVAAIVTDIFNTSDGGRFKFPD...unknowninverse agonist
Sigma non-opioid intracellular receptor 1MQWAVGRRWAWAALLLAVAAVLTQVVWLWLGTQSFVFQREEIAQLARQYA...unknownbinder
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL2111101
PubChem 10071196
ChEMBL CHEMBL2111101
ChEBI CHEBI:133017